Johns Hopkins Center for Health Equity. 5PLUS Nuts + Beans for Kidneys. Updates + helpful resources. https://www.healthequityhub.com/5plus-nuts-beans-for-kidney-home#:~:text=The%20Center%20for%20Health%20Equity’s,pressure%20and%20protect%20the%20kidneys

• PubMed
Johns Hopkins Center for Health Equity. 5PLUS Nuts + Beans for Kidneys. Updates + helpful resources. https://www.healthequityhub.com/5plus-nuts-beans-for-kidney-home#:~:text=The%20Center%20for%20Health%20Equity’s,pressure%20and%20protect%20the%20kidneys )| false
• Search Google Scholar
• Export Citation

Semler MW, et al. Balanced crystalloids versus saline in critically ill adults. N Engl J Med 2018; 378:829–839. doi: 10.1056/NEJMoa1711584

• PubMed
Semler MW, Balanced crystalloids versus saline in critically ill adults. N Engl J Med 2018; 378:829–839. doi: 10.1056/NEJMoa1711584 )| false
• Search Google Scholar
• Export Citation

ClinicalTrials.gov. Saline against lactated Ringers or Plasmalyte in the emergency department (SaLt-ED). Last updated September 15, 2017. https://clinicaltrials.gov/ct2/show/NCT02614040?term=Lactated+Ringers+or+Plasmalyte+in+the+Emergency+Department&draw=2&rank=1

• PubMed
ClinicalTrials.gov. Saline against lactated Ringers or Plasmalyte in the emergency department (SaLt-ED). Last updated September 15, 2017. https://clinicaltrials.gov/ct2/show/NCT02614040?term=Lactated+Ringers+or+Plasmalyte+in+the+Emergency+Department&draw=2&rank=1 )| false
• Search Google Scholar
• Export Citation

ClinicalTrials.gov. Isotonic solutions and major adverse renal events trial in the medical intensive care unit (SMART-MED). Last updated December 16, 2019. https://clinicaltrials.gov/ct2/show/NCT02444988?term=Isotonic+Solutions+and+Major+Adverse+Renal+Events+trial&draw=2&rank=2

• PubMed
ClinicalTrials.gov. Isotonic solutions and major adverse renal events trial in the medical intensive care unit (SMART-MED). Last updated December 16, 2019. https://clinicaltrials.gov/ct2/show/NCT02444988?term=Isotonic+Solutions+and+Major+Adverse+Renal+Events+trial&draw=2&rank=2 )| false
• Search Google Scholar
• Export Citation

Wilson FP, et al. Automated, medication-targeted alerts on AKI outcomes: A multi-center randomized, controlled trial. November 3–6, 2022. Kidney Week 2022. Abstract FR-OR63.

• PubMed
Wilson FP, Automated, medication-targeted alerts on AKI outcomes: A multi-center randomized, controlled trial. November 3–6, 2022. Kidney Week 2022. Abstract FR-OR63. )| false
• Search Google Scholar
• Export Citation

Al-Jaishi AA, et al. Major outcomes with personalized dialysate TEMPerature (MyTEMP): Rationale and design of a pragmatic, registry-based, cluster randomized controlled trial. Can J Kidney Health Dis 2020; 7:2054358119887988. doi: 10.1177/2054358119887988

• PubMed
Al-Jaishi AA, Major outcomes with personalized dialysate TEMPerature (MyTEMP): Rationale and design of a pragmatic, registry-based, cluster randomized controlled trial. Can J Kidney Health Dis 2020; 7:2054358119887988. doi: 10.1177/2054358119887988 )| false
• Search Google Scholar
• Export Citation

Barratt J, et al. Exploratory results from the phase 2 study of cemdisiran in patients with IgA nephropathy. November 3–6, 2022. Kidney Week 2022. Abstract FR-OR67

• PubMed
Barratt J, Exploratory results from the phase 2 study of cemdisiran in patients with IgA nephropathy. November 3–6, 2022. Kidney Week 2022. Abstract FR-OR67 )| false
• Search Google Scholar
• Export Citation

ClinicalTrials.gov. Evaluation of effect of TRC101 on progression of chronic kidney disease in subjects with metabolic acidosis (VALOR-CKD). Last updated October 14, 2022. https://clinicaltrials.gov/ct2/show/NCT03710291?term=VALOR-CKD&draw=2&rank=1

• PubMed
ClinicalTrials.gov. Evaluation of effect of TRC101 on progression of chronic kidney disease in subjects with metabolic acidosis (VALOR-CKD). Last updated October 14, 2022. https://clinicaltrials.gov/ct2/show/NCT03710291?term=VALOR-CKD&draw=2&rank=1 )| false
• Search Google Scholar
• Export Citation

EMPA-KIDNEY Collaborative Group; Herrington WG, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med [published online ahead of print November 4, 2022]. doi: 10.1056/NEJMoa2204233; https://www.nejm.org/doi/10.1056/NEJMoa2204233

• PubMed
EMPA-KIDNEY Collaborative Group; Herrington WG, Empagliflozin in patients with chronic kidney disease. N Engl J Med [published online ahead of print November 4, 2022]. doi: 10.1056/NEJMoa2204233; https://www.nejm.org/doi/10.1056/NEJMoa2204233 )| false
• Search Google Scholar
• Export Citation

Staplin N, et al. Sodium glucose cotransporter-2 (SGLT2) inhibitors among patients with and without diabetes: Collaborative meta-analysis of large placebo-controlled trials. November 3–6, 2022. Kidney Week 2022. Abstract FR-OR69

• PubMed
Staplin N, Sodium glucose cotransporter-2 (SGLT2) inhibitors among patients with and without diabetes: Collaborative meta-analysis of large placebo-controlled trials. November 3–6, 2022. Kidney Week 2022. Abstract FR-OR69 )| false
• Search Google Scholar
• Export Citation

Cha DR, et al. Effect of isuzinaxib, pan NOX inhibitor in patients with type 2 diabetes and CKD in a randomized, double-blind, placebo-controlled phase 2 trial. November 3–6, 2022. Kidney Week 2022. Abstract FR-OR62

• PubMed
Cha DR, Effect of isuzinaxib, pan NOX inhibitor in patients with type 2 diabetes and CKD in a randomized, double-blind, placebo-controlled phase 2 trial. November 3–6, 2022. Kidney Week 2022. Abstract FR-OR62 )| false
• Search Google Scholar
• Export Citation